bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
273 hedge funds and large institutions have $7.92B invested in bluebird bio in 2019 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 106 increasing their positions, 81 reducing their positions, and 42 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 81
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 8.76% → 8.72% (-0.04%)
5% less funds holding
Funds holding: 288 → 273 (-15)
19% less capital invested
Capital invested by funds: $9.81B → $7.92B (-$1.89B)
24% less call options, than puts
Call options by funds: $100M | Put options by funds: $131M
26% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$148M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$127M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$55.8M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$51.3M |
| 5 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$28.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$145M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$74.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$37.1M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$34.5M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$34.1M |
BLUE Hedge Fund Activity: Q2 2019 in Review
273 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2019, worth a combined $7.92B — down 19% from $9.81B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of BLUE and 31 opened new positions — a net loss of 11 holders — while 81 trimmed existing stakes and 106 added.
The largest buyer was Sands Capital Management, opening a new position worth an estimated $148M. The largest seller was Vanguard Group, cutting an estimated $145M.
- 273 institutional investors held bluebird bio (BLUE) as of Q2 2019, down from 288 in Q1 2019.
- Funds reported $7.92B of bluebird bio stock for Q2 2019, down 19% quarter-over-quarter.
- 31 funds opened new bluebird bio positions in Q2 2019 and 42 closed out, a net change of -11 holders.
- The largest bluebird bio buyer in Q2 2019 was Sands Capital Management, an estimated $148M added.
- The largest bluebird bio seller in Q2 2019 was Vanguard Group, an estimated $145M sold.
Based on aggregated 13F filings for Q2 2019.